CIRCULAR & GENERAL MEETING NOTIFICATION

RNS Number : 2175V
Oxford Biomedica PLC
11 December 2013
 



FOR IMMEDIATE RELEASE


 

OXFORD BIOMEDICA PLC

CIRCULAR & GENERAL MEETING NOTIFICATION

 

Oxford UK - 11 December 2013: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB) gives notice that, further to the announcement on 19 November 2013 of the proposed up to £5 million secured loan facility agreement with its largest shareholder, the Vulpes Life Sciences Fund, a circular to shareholders was posted yesterday and is available on the "Investors" section of the Company's website at www.oxfordbiomedica.co.uk.

 

A copy of this document has been submitted to the National Storage Mechanism and will shortly be available for inspection at http://www.hemscott.com/nsm.do.

 

Oxford BioMedica plc also announces that a General Meeting will be held on Monday 6 January 2014 at 10.00 a.m. at the offices of Covington & Burling LLP, 265 Strand, London WC2R 1BH.

 

- Ends -

 

For further information, please contact:


 

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

 

Tel: +44 (0)1865 783 000

 

Media Enquiries:

Mary-Jane Elliott/Emma Thompson/Matthew Neal

Consilium Strategic Communications

 

Tel: +44 (0)20 7920 2354


 

Notes to editors

 

1. About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

MSCEAXAEFSEDFFF